<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402017000100005</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2016.11.003</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diseño de un registro de fibrilación auricular y riesgo embólico en México: CARMEN-AF]]></article-title>
<article-title xml:lang="en"><![CDATA[Design of an atrial fibrillation and embolic risk registry in Mexico: CARMEN-AF]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Hermosillo]]></surname>
<given-names><![CDATA[Jesús A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[Manlio F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ocampo-Peña]]></surname>
<given-names><![CDATA[Salvador]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cardiología «Ignacio Chávez»  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Ángeles de Lindavista  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<volume>87</volume>
<numero>1</numero>
<fpage>5</fpage>
<lpage>12</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402017000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402017000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402017000100005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Objetivo:  La fibrilación auricular (FA) es una de las arritmias más comunes, y su prevalencia aumenta con la edad. Se asocia con alto riesgo de embolia cerebral. La prevención de dichas tromboembolias se realiza mediante anticoagulantes orales, que en nuestro país parecen estar subutilizados. El Registro CARMEN-AF tiene como objetivo primario determinar cuál es el estado actual de la tromboprofilaxis de la FA no valvular en México. Como objetivo secundario pretende conocer la morbimortalidad asociada a la FA no valvular en por lo menos un año de seguimiento.  Métodos:  El Registro CARMEN-AF es un estudio observacional, longitudinal, multicéntrico y nacional sobre el empleo de los anticoagulantes orales en pacientes con FA no-valvular que pretende la inclusión de pacientes mayores de 18 años de edad diagnosticados con FA no valvular durante los últimos 6 meses y con al menos un factor de riesgo para desarrollar una tromboembolia de acuerdo con la escala de CHA2DS2-Vasc. Serán recolectados datos demográficos y clínicos en las visitas clínicas habituales a lo largo de un seguimiento de 2 años. El reclutamiento comenzó el 19 de septiembre de 2014 y se prevé la inclusión del último paciente el 18 de septiembre de 2016. Se estima la inclusión de 1,200 pacientes dada la incidencia de FA reportada a nivel mundial y tomando en consideración la población mexicana total.  Conclusiones:  El registro de FA y riesgo embólico en México (CARMEN-AF) permitirá conocer el estado actual de la tromboprofilaxis en pacientes con FA no valvular y permitirá obtener una panorámica del cumplimiento de las guías nacionales e internacionales de práctica clínica en esta materia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Objective:  Atrial fibrillation (AF) is one of the most common arrhythmias, and its prevalence increase with age. It is associated with high risk of stroke. The prevention of such thromboembolism is done with oral anticoagulants, which in our country seem to be underused. CARMEN-AF registry aims primarily to determine the current status of thromboprophylaxis of non-valvular AF in Mexico. A secondary objective is to know the morbidity and mortality associated with non-valvular AF in at least one year of follow-up.  Methods:  CARMEN-AF registry is an observational, longitudinal, multicenter, and national survey about the use of oral anticoagulants in patients with non-valvular AF. Patients 18 years old or older, diagnosed with AF during the last 6 months, and with at least one risk factor of thromboembolism based in the CHA2DS2-Vasc score are being selected. Demographic and clinical data will be collected during the visits to their usual clinic with a follow-up of 2 years. The recruitment began on September 19, 2014, and the inclusion of the last patient is expected on September 18, 2016. According to the reported incidence of AF globally and taking into account the total Mexican population, the inclusion of 1,200 patients is estimated.  Conclusions:  The Atrial Fibrillation and Embolic Risk Registry (CARMEN-AF) will reveal the current status of thromboprophylaxis in patients with non-valvular AF, and will allow to get an overview of the national and international clinical practice guidelines accomplishment in this area.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Anticoagulantes orales]]></kwd>
<kwd lng="es"><![CDATA[Fibrilación auricular]]></kwd>
<kwd lng="es"><![CDATA[Registro]]></kwd>
<kwd lng="es"><![CDATA[Tromboprofilaxis]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
<kwd lng="en"><![CDATA[Oral anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[Atrial fibrillation]]></kwd>
<kwd lng="en"><![CDATA[Registry]]></kwd>
<kwd lng="en"><![CDATA[Thromboprophylaxis]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kakkar]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bassand]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<source><![CDATA[Am Heart J]]></source>
<year>2012</year>
<volume>163</volume>
<page-range>13&#8211;9</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diseño de un registro multicéntrico para evaluar control de ritmo contra control de la frecuencia en fibrilación auricular: Registro Mexicano de Fibrilación Auricular (ReMeFA)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iturralde-Torres]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lara-Vaca]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cordero-Cabra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2011</year>
<volume>81</volume>
<page-range>13&#8211;7</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Hylek]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>2001</year>
<volume>285</volume>
<page-range>2370&#8211;5</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benjamin]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vaziri]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>1994</year>
<volume>271</volume>
<page-range>840&#8211;4</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guía de práctica clínica. Diagnóstico y tratamiento de la fibrilación auricular]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castaño-Guerra]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Franco-Vergara]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Baca-López]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2012</year>
<volume>50</volume>
<page-range>213&#8211;31</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Pacheco]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Arias-Mendoza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[J Cardiol]]></source>
<year>2015</year>
<volume>66</volume>
<page-range>148&#8211;54</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: Results of the EuroHeart Failure Survey]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivero-Ayerza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Scholte op Reimer]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Theuns]]></surname>
<given-names><![CDATA[DAMJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>2008</year>
<volume>29</volume>
<page-range>1618&#8211;24</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heart disease and stroke statistics &#8211;- 2013 update: A report from the American Heart Association]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Mozaffarian]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Roger]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>127</volume>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuster]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Cannom]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<source><![CDATA[Europace]]></source>
<year>2006</year>
<volume>8</volume>
<page-range>651&#8211;745</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guidelines for the management of atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kirchhof]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J]]></source>
<year>2010</year>
<volume>31</volume>
<page-range>2369&#8211;429</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: A nationwide cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olesen]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Torp-Pedersen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<source><![CDATA[Thromb Haemost]]></source>
<year>2012</year>
<volume>107</volume>
<page-range>1172&#8211;9</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pisters]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Nieuwlaat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Chest]]></source>
<year>2010</year>
<volume>138</volume>
<page-range>1093&#8211;100</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reflexiones sobre la guía clínica en fibrilación auricular]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Flores]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2012</year>
<volume>50</volume>
<page-range>117&#8211;22</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Pearce]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>2007</year>
<volume>146</volume>
<page-range>857&#8211;67</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antithrombotic therapy in atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laupacis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dalen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Feinberg]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Chest]]></source>
<year>1995</year>
<volume>108</volume>
<page-range>352S&#8211;9S</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The influence of patient adherence on anticoagulation control with warfarin. Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kimmel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Intern Med]]></source>
<year>2007</year>
<volume>167</volume>
<page-range>229&#8211;35</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Benavente]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[McBride]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>1999</year>
<volume>131</volume>
<page-range>492&#8211;501</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="">
<source><![CDATA[Demographics and Retirement Policy in Brazil, Chile, and Mexico. Global Aging Initiative. Center for Strategic and International Studies]]></source>
<year>2009</year>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Socioeconomic factors and all cause and cause-specific mortality among older people in Latin America, India, and China: A population-based cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferri]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[PLoS Med]]></source>
<year>2012</year>
<volume>9</volume>
<page-range>e1001179</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Egresos por enfermedad vascular cerebral aguda en instituciones públicas del sector salud de México: Un análisis de 5.3 millones de hospitalizaciones en 2010]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chiquete]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Sandoval]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Murillo-Bonilla]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Mex Neuroci]]></source>
<year>2012</year>
<volume>13</volume>
<page-range>252&#8211;8</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: A commentary]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
</person-group>
<source><![CDATA[J Thromb Haemost]]></source>
<year>2013</year>
<volume>11</volume>
<page-range>615&#8211;26</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation&#8211;-developed with the special contribution of the European Heart Rhythm Association]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[De Caterina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Europace]]></source>
<year>2012</year>
<volume>14</volume>
<page-range>1385&#8211;413</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: Recommendations for stroke prevention and rate/rhythm control]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skanes]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Healey]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Cairns]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Canadian J Cardiol]]></source>
<year>2012</year>
<volume>28</volume>
<page-range>125&#8211;36</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations). A report of the American College of Cardiology/American Heart Association task force on practice guidelines]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Halperin]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>127</volume>
<page-range>1916&#8211;26</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Apixaban versus warfarin in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granger]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<page-range>981&#8211;92</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Dabigatran versus warfarin in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ezekowitz]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<page-range>1139&#8211;51</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rivaroxaban versus warfarin in nonvalvular atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Mahaffey]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Garg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>365</volume>
<page-range>883&#8211;91</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ARISTOTLE RELYs on the ROCKET. What&#8217;s new in stroke prevention in patients with atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tendera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Syzdó&#322;]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Parma]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Cardiol J]]></source>
<year>2012</year>
<volume>19</volume>
<page-range>4&#8211;10</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anticoagulants for atrial fibrillation: why is the treatment rate so low]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buckingham]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Hatala]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Cardiol]]></source>
<year>2002</year>
<volume>25</volume>
<page-range>447&#8211;54</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Transitions of care in anticoagulated patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Michota]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[J Multidiscip Healthc]]></source>
<year>2013</year>
<volume>6</volume>
<page-range>215&#8211;28</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The net clinical benefit of warfarin anticoagulation in atrial fibrillation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Intern Med]]></source>
<year>2009</year>
<volume>151</volume>
<page-range>297&#8211;305</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Atrial fibrillation and thromboprophylaxis in heart failure: The need for patient-centered approaches to address adherence]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Inglis]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Vasc Health Risk Manag]]></source>
<year>2013</year>
<volume>9</volume>
<page-range>3&#8211;11</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Patients&#8217; beliefs about treatment: The hidden determinant of treatment outcome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horne]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[J Psychosom Res]]></source>
<year>1999</year>
<volume>47</volume>
<page-range>491&#8211;5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
